Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

[1]  Kara Nuzback,et al.  Survey results , 2018, Cost Management for Nonprofit and Voluntary Organisations.

[2]  Young Hak Kim,et al.  Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer. , 2011, Lung cancer.

[3]  U. Fuhr,et al.  Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.

[4]  Donna M Hepper,et al.  Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. , 2011, Journal of the American Academy of Dermatology.

[5]  A. Chan,et al.  How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? , 2011, Supportive Care in Cancer.

[6]  B. Piraccini,et al.  Periungual and subungual pyogenic granuloma , 2010, The British journal of dermatology.

[7]  C. Boers-Doets,et al.  Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. , 2010, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[8]  Ximing J. Yang,et al.  Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients , 2010, Clinical Cancer Research.

[9]  Roger T. Anderson,et al.  Effects of epidermal growth factor receptor inhibitor‐induced dermatologic toxicities on quality of life , 2010, Cancer.

[10]  M. Steinhoff,et al.  Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. , 2010, Journal of the American Academy of Dermatology.

[11]  R. Fernández-torres,et al.  Rosaceiform eruption induced by cetuximab. , 2010, European journal of dermatology : EJD.

[12]  J. Ocvirk,et al.  Management of cutaneous side‐effects of cetuximab therapy in patients with metastatic colorectal cancer , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  Lynne Wagner,et al.  A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group , 2010, Supportive Care in Cancer.

[14]  B. Davies,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? , 2009, Anti-cancer drugs.

[15]  E. Van Cutsem,et al.  Skin toxicities of targeted therapies. , 2009, European journal of cancer.

[16]  J. Soria,et al.  Cutaneous side‐effects in patients on long‐term treatment with epidermal growth factor receptor inhibitors , 2009, The British journal of dermatology.

[17]  R. Greil,et al.  Epidermal growth factor receptor (EGFR) inhibitor-related skin toxicity: Review of interim data from a phase II study (20060314) of panitumumab (pmab) with FOLFIRI in the first-line treatment of metastatic colorectal cancer (mCRC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Muro,et al.  A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. , 2009, Japanese journal of clinical oncology.

[19]  M. Lacouture,et al.  NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  E. Van Cutsem,et al.  Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy , 2009, Cancer.

[21]  M. Lacouture,et al.  Increased risk of high‐grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy , 2009, Cancer.

[22]  J. Saurat.  Comprar Dermatologie Et Infections Sexuellement Transmissibles | J-H Saurat | 9782294020995 | Masson , 2009 .

[23]  D. Ghazarian,et al.  Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib. , 2008, Archives of dermatology.

[24]  A. Jatoi,et al.  Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. , 2008, The oncologist.

[25]  D. Sargent,et al.  Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 , 2008, Oncology.

[26]  S. Gregoriou,et al.  Acute and chronic paronychia. , 2008, American family physician.

[27]  M. Gipps,et al.  Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. , 2008, Clinical lung cancer.

[28]  K. Ang,et al.  Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  A. Rademaker,et al.  Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results , 2007, Oncology.

[30]  P. Zimmerman,et al.  Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. , 2007, Oncology.

[31]  J. Bonner,et al.  More on severe cutaneous reaction with radiotherapy and cetuximab. , 2007, The New England journal of medicine.

[32]  B. Homey,et al.  Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  B. Melichar,et al.  Eye complications of cetuximab therapy. , 2007, European journal of cancer care.

[34]  Gary Clark,et al.  Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies , 2007, Clinical Cancer Research.

[35]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Edward S. Kim,et al.  Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. , 2007, The oncologist.

[37]  A. Lavrijsen,et al.  Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. , 2007, European journal of cancer.

[38]  S. Yashar,et al.  Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. , 2007, Journal of the American Academy of Dermatology.

[39]  S. Ménard,et al.  Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  F. Ciardiello,et al.  Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST). , 2007 .

[41]  L. Tanoue,et al.  Erlotinib in Previously Treated Non-Small-Cell Lung Cancer , 2007 .

[42]  Stephen W Dusza,et al.  Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. , 2006, Journal of the American Academy of Dermatology.

[43]  M. Lacouture,et al.  The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome , 2006, The British journal of dermatology.

[44]  M. Lacouture.  Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.

[45]  E. Roé,et al.  Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. , 2006, Journal of the American Academy of Dermatology.

[46]  R. Simcock,et al.  Erlotinib induced skin rash spares skin in previous radiotherapy field. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[48]  Z. Hua.  Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .

[49]  F. Ciardiello,et al.  Cetuximab dose-escalation study in patients with metastatic colorectal cancer (MCRC) with no or slight skin reactions on cetuximab standard dose treatment (Everest): Preliminary PK and efficacy data of a randomized study , 2006 .

[50]  E. Van Cutsem,et al.  Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  R. Perez-soler,et al.  Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Alain Spatz,et al.  Cutaneous side-effects of kinase inhibitors and blocking antibodies. , 2005, The Lancet. Oncology.

[53]  A. Halpern,et al.  HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. , 2005, The oncologist.

[54]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  H. Swaisland,et al.  Development of the Novel Biologically Targeted Anticancer Agent Gefitinib , 2004, Clinical Cancer Research.

[56]  M. Ychou,et al.  Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours , 2004, The British journal of dermatology.

[57]  D. Stulberg,et al.  Common hair loss disorders. , 2003, American family physician.

[58]  R. Derynck,et al.  Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor , 1995, Nature.